Teclistamab Receives Accelerated Approval for Relapsed/Refractory Multiple Myeloma
Keira Smith
FDA Updates
The FDA has granted accelerated approval to teclistamab-cqyv (Tecvayli®, Janssen Biotech) for adult patients with relapsed/refractory multiple myeloma previously treated with four or more lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Teclistimab is the first bispecific B-cell ma...
Elevating Proficiency of Evolving Treatment Options for Advanced Hodgkin Lymphoma
Lyn Brook
Practice Patterns
i3 Health has provided an educational activity that has alleviated clinician's knowledge gaps pertaining to the evolving landscape of advanced classical Hodgkin lymphoma (HL). Hodgkin lymphoma is a malignancy involving the lymph nodes and lymphatic system. The American Cancer Society estimated in 2022 that there would be 8,540 new cases of HL in th...
Increasing Expertise for Treatment of Non-Hodgkin Lymphoma
Lyn Brook
Practice Patterns
An educational activity provided by i3 Health has bridged knowledge gaps experienced by nursing professionals and other health care professionals on the topic of treatment strategies for patients with non-Hodgkin lymphoma (NHL). Accounting for 4% of all cancers diagnosed, NHL is one of the most common cancer types in the United States. The American...
Staying Up to Date on Management of Tumor Lysis Syndrome With Amy Goodrich, MSN, RN, CRNP
Lyn Brook
Expert Analysis
Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected. In this interview, Amy Goodrich, MSN, RN, CRNP, a Nurse Practitioner and Research Nursing Manager at the Johns Hopkins Kimmel Cancer Center, discusses a recent educational activity she co-led, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies. 
Upgrades in Understanding Therapeutic Strategies for Graft-Versus-Host Disease
Lyn Brook
Practice Patterns
An educational enduring online activity provided by i3 Health has provided efficiency and knowledge gains encompassing the evolving landscape of therapeutic strategies for graft-versus-host disease (GVHD). Graft-versus-host disease is a complication of allogeneic hematopoietic stem cell transplant (HSCT), affecting between 40% and 60% of patients a...
Conquering Knowledge Gaps Concerning Therapeutic Advances in T-Cell Lymphoma
Lyn Brook
Practice Patterns
A learning opportunity provided by i3 Health has demonstrated significant knowledge gains regarding therapeutic advances in T-cell lymphoma (TCL). T-cell lymphoma is a rare type of non-Hodgkin lymphoma with many different subtypes, including peripheral TCL, anaplastic large cell lymphoma, adult T-cell leukemia/lymphoma, angioimmunoblastic TCL, and ...

Copyright © 2022 Oncology Data Advisor. All rights reserved.